Drug updated on 4/26/2024
| Dosage Form | Injection (subcutaneous; 50 mcg/mL, 100 mcg/mL) |
| Drug Class | Glucagon-like peptide 1 (GLP-1) receptor agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Summary
- Lixisenatide (Adlyxin) is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It has shown mixed results when compared to other glucagon-like peptide-1 receptor agonists (GLP-1 RAs), demonstrating favorable outcomes in reducing glycated hemoglobin and achieving glycemic targets, especially when used in fixed-ratio combinations or compared to premix insulin.
- Eleven systematic reviews/meta-analyses focused on the efficacy and safety of lixisenatide, particularly its use among adults with type 2 diabetes mellitus.
- In terms of cardiovascular events, lixisenatide was associated with reductions but showed variability in effectiveness. Subcutaneous semaglutide and albiglutide were often more effective than lixisenatide among patients with cardiovascular disease or chronic kidney disease.
- The impact of lixisenatide on weight management varied; some comparisons showed less weight reduction compared to other GLP-RAs like oral semaglutide. However, fixed-ratio combinations involving this drug tended towards favorable outcomes regarding body weight management.
- Gastrointestinal intolerance was a common concern across all GLP-RAs, including Adlyxin; however, it generally had lower rates of nausea/vomiting than exenatide or liraglutide, especially when used alongside insulin glargine, which could enhance gastrointestinal tolerability.
- Variability in benefits from using GLP-RAs such as Adlyxin can occur according to patient baseline characteristics, such as duration/history of diabetes, renal function, or cardiovascular diseases, showing pronounced benefits for cerebrovascular outcomes amongst those having shorter durations or higher eGFRs.
- The prevention efficiency against cardiovascular events and progression of renal diseases varies between drugs/subgroups: subcutaneous semaglutides and albiglutides were particularly effective for patients with cardiovascular diseases, while canagliflozin and liraglutide showed pronounced benefits in those having chronic kidney disease.
- Lixisenatide (Adlyxin) offers potential benefits in weight management when used appropriately. Its safety and tolerability profile is comparable to other agents within the class, with certain fixed-ratio combinations possibly offering enhanced gastrointestinal tolerability.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Adlyxin (lixisenatide) Prescribing Information. | 2023 | Sanofi-Aventis U.S. LLC, Bridgewater, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2023. | 2023 | American Diabetes Association |
| 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes. | 2023 | Diabetology & Metabolic Syndrome |
| 2023 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. | 2023 | Diabetes and Metabolism Journal |
| Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | 2022 | Diabetes Care |
| Recent updates to clinical practice guidelines for diabetes mellitus. | 2022 | Endocrinology and Metabolism |
| 2021 Clinical practice guidelines for diabetes mellitus in Korea. | 2021 | Diabetes and Metabolism Journal |
| Japanese clinical practice guideline for diabetes 2019. | 2019 | Journal of Diabetes Investigation |